An acquisition and changes to the executive committee for Novartis

The merger between AveXis and Novartis AM Merger Corporation completed the procedure of acquisition by Novartis, giving access to AveXis’ portfolio of leading gene therapy technology and the first one-time gene-based treatment for spinal muscular atrophy in children.

Novartis also announced the retirement of the Group General Counsel Felix R. Ehrat, being effective since June 1, 2018. Shannon Thyme Klinger has been appointed as the new Group General Counsel. Robert Weltevreden has also been appointed as Head of Novartis Business Services (NBS).